Evidence map›Paper›PMID 37188311›Full record

ArticleFrontiers in neurology2023

Predictive model of recurrent ischemic stroke: model development from real-world data.

Marwa Elsaeed Elhefnawy, Siti Maisharah Sheikh Ghadzi, Orwa Albitar, Balamurugan Tangiisuran, Hadzliana Zainal, Irene Looi, Norsima Nazifah Sidek, Zariah Abdul Aziz, Sabariah Noor Harun

Abstract read
In one paragraph

Article in Frontiers in neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Marwa Elsaeed ElhefnawySchool of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia.
Siti Maisharah Sheikh GhadziSchool of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia.
Orwa AlbitarSchool of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia.
Balamurugan TangiisuranSchool of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia.
Hadzliana ZainalSchool of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia.
Irene LooiClinical Research Center, Hospital Seberang Jaya, Penang, Malaysia.
Norsima Nazifah SidekClinical Research Centre, Hospital Sultanah Nur Zahirah, Terengganu, Malaysia.
Zariah Abdul AzizClinical Research Centre, Hospital Sultanah Nur Zahirah, Terengganu, Malaysia.
Sabariah Noor HarunSchool of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: There are established correlations between risk factors and ischemic stroke (IS) recurrence; however, does the hazard of recurrent IS change over time? What is the predicted baseline hazard of recurrent IS if there is no influence of variable predictors? This study aimed to quantify the hazard of recurrent IS when the variable predictors were set to zero and quantify the secondary prevention influence on the hazard of recurrent ischemic stroke. Methods: In the population cohort involved in this study, data were extracted from 7,697 patients with a history of first IS attack registered with the National Neurology Registry of Malaysia from 2009 to 2016. A time-to-recurrent IS model was developed using NONMEM version 7.5. Three baseline hazard models were fitted into the data. The best model was selected using maximum likelihood estimation, clinical plausibility, and visual predictive checks. Results: Within the maximum 7.37 years of follow-up, 333 (4.32%) patients had at least one incident of recurrent IS. The data were well described by the Gompertz hazard model. Within the first 6 months after the index IS, the hazard of recurrent IS was predicted to be 0.238, and 6 months after the index attack, it reduced to 0.001. The presence of typical risk factors such as hyperlipidemia [HR, 2.22 (95%CI: 1.81-2.72)], hypertension [HR, 2.03 (95%CI: 1.52-2.71)], and ischemic heart disease [HR, 2.10 (95%CI: 1.64-2.69)] accelerated the hazard of recurrent IS, but receiving antiplatelets (APLTs) upon stroke decreased this hazard [HR, 0.59 (95%CI: 0.79-0.44)]. Conclusion: The hazard of recurrent IS magnitude differs during different time intervals based on the concomitant risk factors and secondary prevention.

Indexed as

ischemic strokeNONMEMpharmacometricsrecurrenttime to event model

Identifiers

PMID37188311
PMCPMC10176964

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.